“Continuous Tralokinumab Treatment over 4 Years in Adults with Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control”, J of Skin, vol. 8, no. 2, p. s376, Mar. 2024, doi: 10.25251/skin.8.supp.376.